Glucose-6-phosphate: a key compound in glycogenosis I and favism leading to hyper- or hypolipidaemia
- PMID: 8319730
- DOI: 10.1007/BF02072094
Glucose-6-phosphate: a key compound in glycogenosis I and favism leading to hyper- or hypolipidaemia
Abstract
The glycogen storage disorders (GSD)-I, -III, -VI and -VIII are associated with hypertriglyceridaemia or mixed hyperlipidaemia which poses the question whether these patients have an increased risk for atherosclerosis. The atherogenicity of triglycerides has remained controversial, while increased plasma cholesterol levels are generally accepted as a significant risk factor for coronary heart disease. However, clinical data show that one has to differentiate between metabolic conditions where triglycerides are atherogenic and those which are not significantly related to early onset of atherosclerosis but may cause other disorders such as pancreatitis. Among the disorders of carbohydrate metabolism patients with diabetes mellitus frequently have enhanced plasma triglycerides associated with a higher risk for coronary heart disease, while patients with certain types of glycogen storage disease have high triglyceride levels but do not seem to have an enhanced risk for atherosclerosis. Here we have compared the biochemical abnormalities and the atherogenic risk of three different disorders of glucose metabolism including GSD-I (glucose-6-phosphatase deficiency), favism (glucose-6-phosphate dehydrogenase deficiency), and diabetes mellitus which are related to either hyper- or hypolipidaemia. The available data indicate that glucose-6-phosphate (Glc-6-P) is a central molecule in cellular glucose metabolism which critically influences pentose phosphate cycle activity and, via NADPH2-generation, regulates glutathione peroxidase activity for radical detoxification and also cholesterol and triglyceride synthesis. Radical detoxification is a major protective factor for cell membrane integrity and together with an appropriate renewal of membrane lipids may protect against the development of atherosclerosis.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Disturbed lipid metabolism in glycogen storage disease type 1.Eur J Pediatr. 2002 Oct;161 Suppl 1:S65-9. doi: 10.1007/s00431-002-1007-8. Epub 2002 Jul 13. Eur J Pediatr. 2002. PMID: 12373575 Review.
-
[CHOLEGLOBIN FORMATION IN THE ERYTHROCYTES OF PATIENTS WITH FAVISM (WITH GRAVE DEFICIENCY OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE). INFLUENCE OF THE AVAILABILITY OF GLUCOSE-6-PHOSPHATE].Boll Soc Ital Biol Sper. 1963 Oct 15;39:1080-3. Boll Soc Ital Biol Sper. 1963. PMID: 14116473 Italian. No abstract available.
-
Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a.Pediatr Res. 2008 Jun;63(6):702-7. doi: 10.1203/PDR.0b013e31816c9013. Pediatr Res. 2008. PMID: 18520334 Clinical Trial.
-
Ischemic stroke in an adult with glycogen storage disease type I.J Clin Neurosci. 2010 Nov;17(11):1467-9. doi: 10.1016/j.jocn.2010.03.026. Epub 2010 Aug 10. J Clin Neurosci. 2010. PMID: 20699197
-
Secondary metabolic changes in von Gierke's disease (Type I glycogen storage disease).Ann Clin Lab Sci. 1982 Sep-Oct;12(5):424-30. Ann Clin Lab Sci. 1982. PMID: 6753728 Review.
Cited by
-
Glomerular and tubular function in glycogen storage disease.Pediatr Nephrol. 1995 Dec;9(6):705-10. doi: 10.1007/BF00868717. Pediatr Nephrol. 1995. PMID: 8747109 Clinical Trial.
-
The hepatic glycogen storage diseases--problems beyond childhood.J Inherit Metab Dis. 1995;18(4):462-72. doi: 10.1007/BF00710057. J Inherit Metab Dis. 1995. PMID: 7494404 Review.
-
The Effects of Cordyceps sinensis (Berk.) Sacc. and Gymnema inodorum (Lour.) Decne. Extracts on Adipogenesis and Lipase Activity In Vitro.Evid Based Complement Alternat Med. 2019 Apr 1;2019:5370473. doi: 10.1155/2019/5370473. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31057650 Free PMC article.
-
Blood lipids and endothelial function in glycogen storage disease type III.J Inherit Metab Dis. 1999 Dec;22(8):891-8. doi: 10.1023/a:1005687323096. J Inherit Metab Dis. 1999. PMID: 10604141 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical